Skip to main content
. 2016 Jan 12;34(4):788–797. doi: 10.1097/HJH.0000000000000839

TABLE 2.

Ambulatory blood pressure results by treatment group and pool

Variable Normoglycemic subgroup Prediabetes mellitus subgroup T2DM subgroup
Pool A SBP Placebo AZL-M 40 mg AZL-M 80 mg OLM 40 mg Placebo AZL-M 40 mg AZL-M 80 mg OLM 40 mg Placebo AZL-M 40 mg AZL-M 80 mg OLM 40 mg
Baseline (mmHg) 146 146 145 146 145 145 146 146 147 144 146 144
Δ (mmHg) −0.8 ± 1.1 −15.1 ± 0.9* −14.2 ± 0.8* −13.2 ± 0.8* −1.8 ± 1.0 −13.4 ± 0.8* −16.8 ± 0.8*,§ −12.9 ± 0.7* 0.5 ± 1.7 −12.1 ± 1.0* −12.3 ± 1.1* −9.8 ± 1.2*
Pool A DBP Placebo AZL-M 40 mg AZL-M 80 mg OLM 40 mg Placebo AZL-M 40 mg AZL-M 80 mg OLM 40 mg Placebo AZL-M 40 mg AZL-M 80 mg OLM 40 mg
Baseline (mmHg) 90 90 89 89 86 87 88 88 89 85 86 84
Δ (mmHg) −0.1 ± 0.7 −9.7 ± 0.6* −8.6 ± 0.5* −8.5 ± 0.5* −1.1 ± 0.7 −8.2 ± 0.5* −10.5 ± 0.5*,§ −7.9 ± 0.5* +0.7 ± 1.1 −7.1 ± 0.7* −7.3 ± 0.7* −5.4 ± 0.7*
N 100 173 200 203 114 200 184 216 40 108 88 85
Pool B SBP Placebo AZL-M 40 mg AZL-M 80 mg VAL 320 mg Placebo AZL-M 40 mg AZL-M 80 mg VAL 320 mg Placebo AZL-M 40 mg AZL-M 80 mg VAL 320 mg
Baseline (mmHg) 145 145 145 144 144 145 144 145 146
Δ (mmHg) −15.0 ± 0.8§ −15.4 ± 0.8§ −11.1 ± 0.8 −13.3 ± 0.8†† −15.1 ± 0.9§ −10.9 ± 0.8 −11.8 ± 1.1 –12.0 ± 1.2 –10.1 ± 1.2
Pool B DBP Placebo AZL-M 40 mg AZL-M 80 mg VAL 320 mg Placebo AZL-M 40 mg AZL-M 80 mg VAL 320 mg Placebo AZL-M 40 mg AZL-M 80 mg VAL 320 mg
Baseline (mmHg) 90 89 89 86 87 87 83 86 87
Δ (mmHg) −9.8 ± 0.6 −10.0 ± 0.5 −7.4 ± 0.6 −8.2 ± 0.6 −9.7 ± 0.6 −6.9 ± 0.6 −6.8 ± 0.7 −7.7 ± 0.8 −6.0 ± 0.8
N 211 215 199 202 175 201 102 99 96

Data are LS mean ± standard error (SE). AZL-M, azilsartan medoxomil; OLM, olmesartan; VAL, valsartan. Δ = change from baseline.

*P 0.001 versus placebo.

P 0.01 versus OLM/VAL.

P < 0.05 versus OLM/VAL.

§P 0.001 versus OLM/VAL.

††P = 0.03 versus VAL.